Sign In

Avery Sonnenberg

Principal at Two Bear Capital

Avery Sonnenberg is a distinguished professional with a strong educational background in Bioengineering and Biomedical Engineering, holding a Doctor of Philosophy (PhD) degree from the University of California San Diego and Master of Science (M.S.) degrees from both UC San Diego and the Rochester Institute of Technology.

With a Bachelor of Science (B.S.) in Electrical and Electronics Engineering also from the Rochester Institute of Technology, Avery has a well-rounded academic foundation.

Avery currently serves as a Principal at Two Bear Capital, showcasing excellent expertise in the field of capital management and investment.

His previous roles include significant positions at BD, where he worked as a Staff Engineer, Senior Engineer, and Research Associate, demonstrating a deep understanding of engineering practices.

Before his tenure at BD, Avery served as a Senior R&D Engineer at BioMedomics, Inc., enhancing his experience in research and development within the biomedical industry.

Not only limited to engineering, Avery also has experience in rescue operations, having served as a Rescue Member at the San Diego Mountain Rescue Team.

During his academic journey, Avery also engaged in graduate studies at UC San Diego, further enriching his knowledge and skills in the field.

Avery Sonnenberg's diverse background and robust experience make him a valuable asset in various professional settings, from engineering and research to capital management and rescue operations.

Highlights

Jul 16 · linkedin

Have you heard of Shingrix? It's an FDA-approved vaccine for the prevention of shingles which is over 90% effective, reducing the burden of this painful condition (while generating over $4B for GSK in 2023!).

Why does Shingrix work so well? It uses GSK's incredible AS01 adjuvant system, which allows vaccines to use antigens that may not otherwise generate a strong enough immune response.

What could we do with easier access to powerful adjuvant systems like GSK's AS01?

With this new agreement between Inimmune and SPI Pharma, we're about to find out:

https://lnkd.in/gycB9GYe

Congratulations to ALAN JOSLYN, Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter, Michael Conger, Mike Sullivan and the rest of the Inimmune team!

Avery Sonnenberg
Add to my network

Location

Whitefish, Montana, United States